IPI-549 is primarily investigated for its potential in cancer therapy, particularly as an immuno-oncology agent. It functions as a selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-γ), which plays a crucial role in modulating the tumor microenvironment. By targeting PI3K-γ, IPI-549 aims to enhance the body’s immune response against tumors, promoting anti-tumor immunity. This makes it a promising candidate for combination therapies with immune checkpoint inhibitors, potentially improving outcomes in patients with solid tumors. Research is ongoing to explore its efficacy in various cancer types, including those resistant to conventional treatments.